On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC).To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of local administration of bel-sar alone (n=5) and bel-sar with light activation (n=8).Also Read: Aura Biosciences Touts Promising Data From Eye Cancer Candidate.The secondary endpoints are to evaluate biological activity and immune ...